New recommendations on hoarseness for primary care physicians

Oct 05, 2009

Primary care physicians face limitations when evaluating patients for voice problems including hoarseness (dyphonia), according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA.

The authors discovered that among 271 , only a third (36.5%) routinely evaluated their patients for voice problems. Nearly one in five (18.1%) never evaluate their patient for a voice disorder. These physicians cited a variety of reasons, including a lack of patient complaint, more pressing issues, or not feeling comfortable with assessing voice ailments. However, over two-thirds expressed an interest in learning more about voice problems.

Voice disorders will affect approximately 30 percent of patients in their lifetimes, severely impacting their qualities of life and contributing to significant decreases in work productivity. However, only a minority of these patients will seek treatment, highlighting the need for improved methods for identifying and treating these patients.

The research coincides with the AAO-HNS' release of the first multi-discipline clinical guidelines for treating hoarseness in patients.

Source: American Academy of Otolaryngology

Explore further: 'Beach body' ads investigated after outcry in Britain

Related Stories

National guideline released for the treatment of hoarseness

Sep 01, 2009

The American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) will issue the first--and only--national clinical practice guideline to help healthcare practitioners identify and manage patients with ...

Recommended for you

Dutch DSM posts Q1 slump

Apr 29, 2015

Dutch pharmaceutical group DSM posted a 70 million euro first quarter net loss Wednesday despite an 11 percent jump in sales, boosted by higher animal nutrition volumes and favourable exchange rates.

New meds help drugmakers weather strong dollar, other issues

Apr 28, 2015

Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers Squibb ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.